Conference Coverage EHA 2022 – Focus on Multiple Myeloma

The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?

June 13, 2022

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ, USA

Faculty Members



  • First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
  • First Line (2): Induction in Transplant-Eligible Multiple Myeloma
  • First Line (3): Maintenance and MRD
  • Relapsed/Refractory Multiple Myeloma: First and Second Relapse
  • Relapsed/Refractory Multiple Myeloma: Novel Agents
  • Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics
  • Relapsed/Refractory Multiple Myeloma: CAR Ts

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.